Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that research related to its antibody-drug conjugate (ADC) technology was presented at the 103 rd Annual Meeting of the American Association for Cancer Research (AACR) being held in Chicago, IL. The presentations highlighted data from an ADC using a potent new cytotoxic agent that can be linked to antibodies, a method to produce uniform drug-loading on antibodies with enhanced stability and a novel preclinical ADC targeted to solid tumors. In addition, data were presented showing the antitumor activity of a novel fucose inhibitor that can be administered orally.
“Our presentations at AACR highlight several significant discoveries that could augment or complement our auristatin-based ADC platform, including the introduction of a novel DNA-crosslinking agent and an engineered cysteine antibody that increases linker stability and uniformity of drug-loading,” said Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine at Seattle Genetics. “In parallel, we are working to advance a growing pipeline of preclinical programs, which includes an integrin expressed on multiple solid tumors. We are committed to advancing the field of ADCs in order to improve the lives of people with cancer, and we believe our research moves us closer to achieving this goal.”
ADCs are monoclonal antibodies that selectively deliver potent cell-killing agents to tumor cells. With over a decade of experience and knowledge in ADC innovation, Seattle Genetics has developed proprietary technology employing synthetic cell-killing agents called auristatins (such as monomethyl auristatin E [MMAE] and monomethyl auristatin F [MMAF]) and stable linker systems that attach auristatins to the antibody. Seattle Genetics’ linker systems are designed to be stable in the bloodstream and release the cell-killing agent once inside targeted cancer cells. This approach is intended to spare non-malignant cells and reduce many of the toxic effects of traditional chemotherapy while enhancing antitumor activity. ADCETRIS™ (brentuximab vedotin) is the first drug approved utilizing Seattle Genetics’ auristatin-based ADC technology.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV